Managing Bone Disease

Core Conclusion

Approximately 80% of multiple myeloma patients present with osteolytic bone lesions. Monthly bone-modifying agents like zoledronic acid (4 mg) or denosumab (120 mg) reduce skeletal-related events and fracture risk by 40% to 50%.

Detailed Points

(1) The Mechanism of Bone Disease (Why Bones Get Weakened) In a healthy body, there is a perfect, continuous balance between "osteoclasts" (cells that break down old bone tissue) and "osteoblasts" (cells that build new bone). Myeloma cells hijack this system by releasing chemicals that push the bone-eating osteoclasts into overdrive while simultaneously paralyzing the bone-building osteoblasts. This aggressive breakdown leaves soft spots or "holes" in the bones—called lytic lesions—making them thin, weak, and prone to breaking, while also releasing dangerous amounts of calcium into your bloodstream (hypercalcemia).

(2) The Rationale and Duration for Zoledronic Acid vs. Denosumab To stop this bone destruction, your doctor will prescribe a Bone-Modifying Agent (BMA) to be taken alongside your primary myeloma treatment.

• Zoledronic Acid (Zometa): This is a traditional intravenous (IV) bisphosphonate that works by destroying the overactive osteoclasts. However, because it is cleared from the body through the kidneys, it is absolutely not recommended if you have severe kidney impairment (creatinine clearance < 30 mL/min).
• Denosumab (Xgeva): This is a monoclonal antibody given as a monthly injection under the skin (120 mg). It works differently by blocking a specific protein (RANKL) that osteoclasts need to survive. It is the preferred, safer choice if you have kidney problems. However, because it is so potent, it carries a higher risk of causing a severe drop in blood calcium levels (hypocalcemia occurs in about 17% of patients), so your doctor will closely monitor your blood and require you to take calcium and Vitamin D supplements.
• Duration: Treatment is generally given monthly for up to 2 years. Depending on how well your myeloma responds, your doctor might later decrease the frequency (e.g., to every 3 months) or stop the drug. Crucial warning: If you stop taking denosumab, you must receive a follow-up dose of a bisphosphonate or continue denosumab every 6 months to prevent a dangerous "rebound" effect that causes rapid bone loss and vertebral fractures.

(3) Prevention of Osteonecrosis of the Jaw (ONJ) Both medications carry a rare but serious risk of Osteonecrosis of the Jaw (ONJ), a condition where a section of the jawbone becomes exposed and is very slow to heal. To prevent this, you must have a comprehensive dental examination and complete any major dental work (like tooth extractions) before you begin bone therapy. Once on treatment, maintaining excellent daily oral hygiene, scheduling regular dental check-ups, and informing your dentist about your medications are your absolute best defenses.

(4) Prevention of Pathologic Fractures The most effective way to prevent fractures is through the consistent use of your bone-modifying medications. Additionally, guidelines recommend taking calcium and Vitamin D supplements to maintain bone strength and engaging in cautious weight-bearing exercises as cleared by your doctor. Your medical team will also use advanced imaging (like MRI or low-dose CT scans) to proactively look for large, unstable lesions that are at imminent risk of fracturing, allowing them to intervene before a break happens. (Note: While utilizing a firm mattress and practicing fall prevention are excellent, practical home-safety measures often recommended by physical therapists, the clinical medical guidelines emphasize imaging and medical therapies as the primary prevention tools).

(5) When Orthopedic Surgery or Localized Radiation is Needed

• Surgery: If you develop a painful compression fracture in your spine, doctors can perform a minimally invasive procedure called balloon kyphoplasty or vertebroplasty. This involves injecting medical-grade cement into the broken vertebra to restore its height, stabilize the spine, and rapidly relieve pain. Orthopedic surgery (like placing a supportive rod) is also highly recommended if a long bone, like your femur, breaks or is at imminent risk of snapping.
• Radiation: Low-dose localized radiation (up to 30 Gy) is an outstanding palliative tool. It is used to shrink localized myeloma tumors that are causing severe, uncontrolled bone pain or to relieve pressure if a tumor is pushing dangerously against your spinal cord.

(6) Graded Pain Management Strategies Managing bone pain requires a dedicated, multidisciplinary approach. Pain is usually directly related to the "tumor burden" in your bones. Over time, effective myeloma chemotherapy and bone-modifying agents will heal the bone and fade the pain. For immediate, daily comfort, your specialist or a dedicated pain management team will help you safely balance prescription pain medications or over-the-counter (OTC) pain relievers. You must always consult your doctor before taking any OTC pain medications, as drugs like NSAIDs (ibuprofen, naproxen) can be highly toxic to a myeloma patient's kidneys.

The above content is sourced from the following references

• Patient Handbook
• Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia
• EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
• NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma
• NCCN Guidelines for Patients® Multiple Myeloma
• Singapore Myeloma Study Group consensus guidelines for the management of patients with multiple myeloma
• Management of multiple myeloma-related renal impairment recommendations from the International Myeloma Working Group
• MMRF-Disease-Overview_patient-toolkit